"We are excited to announce the addition of Denis to the Regulus leadership team," said Jay Hagan, CEO of Regulus. "Denis brings nearly 20 years of drug discovery and development experience to the company, working with both small molecule and neucleic acid based therapeutics. Denis will be a tremendous asset to our company as we leverage our platform technology and build our pipeline."
"With microRNA based therapeutics being on the cusp of shifting the treatment paradigm for multiple indications with high unmet medical need, Regulus is uniquely positioned to become a pioneer in bringing new therapeutic options to the patients," said
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the potential of microRNA therapeutics. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs, and feedback from the FDA. In addition, while Regulus expects the COVID-19 pandemic to adversely affect its business operations and financial results, the extent of the impact on Regulus' ability to achieve its preclinical and clinical development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the
View original content to download multimedia:http://www.prnewswire.com/news-releases/regulus-therapeutics-appoints-denis-drygin-phd-as-chief-scientific-officer-301104281.html
Cris Calsada, Chief Financial Officer, 858-202-6376, firstname.lastname@example.org